Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Deals

Boston Scientific Set to Acquire Bolt Medical for Up to USD 900 Million

Fineline Cube Jan 9, 2025

US major Boston Scientific Corporation (NYSE: BSX) is set to acquire Bolt Medical, Inc., a...

Company Policy / Regulatory

China’s Central Committee and State Council Outline Reforms for Elderly Care Services

Fineline Cube Jan 9, 2025

The Communist Party of China (CPC) Central Committee and State Council have released the Opinions...

Company Deals

Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery

Fineline Cube Jan 9, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary...

Policy / Regulatory

Shanghai Opens Door to Wholly Foreign-Owned Hospitals in Key Areas

Fineline Cube Jan 9, 2025

The Shanghai Municipal Health Commission, along with three other bureaus, has jointly released the “Work...

Policy / Regulatory

NHSA Strengthens Medical Security Rights for Workers in China

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Notice on Further Strengthening the Protection...

Company Deals

Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418

Fineline Cube Jan 8, 2025

On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced...

Company Drug

MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26

Fineline Cube Jan 8, 2025

US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received...

Company Drug

Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication

Fineline Cube Jan 8, 2025

Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...

Company Medical Device

GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China

Fineline Cube Jan 8, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals Drug

Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Fineline Cube Jan 8, 2025

US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...

Company Deals

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors

Fineline Cube Jan 8, 2025

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance...

Company Deals

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies

Fineline Cube Jan 8, 2025

China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...

Company Deals

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project

Fineline Cube Jan 8, 2025

Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution...

Company Deals

Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project

Fineline Cube Jan 8, 2025

Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...

Company Deals

LinkedCare Raises Hundreds of Millions in Series E Funding Led by State-Owned Investors

Fineline Cube Jan 8, 2025

LinkedCare, a consumer healthcare SaaS+ supply chain platform based in Shanghai, has reportedly raised “hundreds...

Company Deals

Grand Life Sciences Partners with Cali Biosciences for CPL-01 Commercialization in China

Fineline Cube Jan 8, 2025

China-based Grand Life Sciences has entered into a partnership with compatriot firm Cali Biosciences Co.,...

Company Drug

Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease

Fineline Cube Jan 8, 2025

China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...

Company Deals

GlycoNex Licenses SPD8 Biosimilar to Undisclosed Company for Osteoporosis Treatment

Fineline Cube Jan 8, 2025

Taiwan-based GlycoNex, Inc. (TPEx: 4168) has announced a licensing agreement with an undisclosed company for...

Company Drug

Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction

Fineline Cube Jan 8, 2025

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...

Company Drug

Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC

Fineline Cube Jan 8, 2025

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...

Posts pagination

1 … 284 285 286 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.